Navigation Links
Cadence Pharmaceuticals Comments on USPTO's Non-Final, Initial Office Action on Reexamination of Patent
Date:8/15/2013

SAN DIEGO, Aug. 15, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) today announced that the United States Patent and Trademark Office (USPTO), has issued a non-final, initial office action in the Ex Parte Reexamination of US Patent No. 6,028,222, or the '222 patent, one of the two licensed patents covering OFIRMEV® (acetaminophen) injection. Although the USPTO made an initial determination to reject certain claims, all of the claims of the '222 patent remain valid and in force until the USPTO issues a final action in this reexamination.

"This initial office action by the USPTO is not a final decision, rather, it's just one step in the reexamination process, which can take many years to complete. It's very common for the USPTO to reject some or all of the claims of a patent in an initial office action, however, claims that are initially rejected may be subsequently allowed. Importantly, we don't expect this action to have an adverse impact on the pending litigation against Exela," said Ted Schroeder, President and CEO of Cadence. "We strongly believe that the scope and validity of the patent claims in the '222 patent are appropriate and that the USPTO's prior issuance of the patent was correct."

The '222 patent covers the formulation of OFIRMEV, and expires in August 2017, and US Patent No. 6,992,218, covers the process used to manufacture OFIRMEV, and expires in June 2021. Upon completion of the company's ongoing pediatric clinical trial of OFIRMEV, both patents will be eligible for an additional six months of marketing exclusivity. In September 2012, a third party filed with the USPTO a Request for Ex Parte Reexamination of the '222 patent, and in December 2012, Cadence received notice that the USPTO had granted the Request for Reexamination. The reexamination process requir
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cadence Pharmaceuticals Appoints Laureen DeBuono to its Board of Directors
2. Cadence Pharmaceuticals To Present At The 2013 Wedbush PacGrow Life Sciences Management Access Conference On August 13, 2013
3. Cadence Pharmaceuticals Reports Second Quarter 2013 Financial Results
4. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Second Quarter 2013 Financial Results On July 31, 2013
5. Cadence Pharmaceuticals To Present At Three Investment Conferences During The Month Of May 2013
6. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss First Quarter 2013 Financial Results On May 2, 2013
7. Cadence Pharmaceuticals Appoints Stephen L. Newman, M.D., to its Board of Directors
8. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results
9. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013
10. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013
11. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Leerink Swann Global Healthcare Conference In New York City On February 13, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... PALO ALTO, Calif. , Dec, 22, 2014 ... of a Phase 2a study of lonafarnib in ...  The study was conducted at the National Institutes ... Bethesda, Maryland .  The double-blinded, randomized, placebo-controlled, ... 100 mg twice daily and 200 mg twice ...
(Date:12/22/2014)... TWi Biotechnology, Inc., today announced that ... TWi Biotechnology,s lead drug candidate, from The State ... for patent application numbered 201180018154.8.  This patent ... metabolite for treatment of type II diabetes.  The ... AC-201 for type II diabetes, and provides a ...
(Date:12/19/2014)...  Newport Corporation (NASDAQ: NEWP ) ... the company,s Board of Directors.  Dr. Kadia is ... of Evans Analytical Group, a leading global provider ... to companies in a wide range of industries.   ... Group, Dr. Kadia spent nine years with Life ...
Breaking Medicine Technology:Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2
... 2010 CareFusion (NYSE: ... today launched the EnVe™ ventilator , a ... 70-80 pounds lighter than other ventilators with similar ... The EnVe ventilator has the capability to ...
... Dec. 20, 2010 Codexis, Inc. (Nasdaq: CDXS ... Jaffray Clean Technology & Renewables Conference, to be held in ... be made by Robert Lawson, Senior Vice President and Chief ... noon Eastern Time.  A webcast and replay will be available ...
Cached Medicine Technology:CareFusion Launches EnVe Ventilator, Weighing 10 Times Less Than Traditional Critical Care Ventilators 2CareFusion Launches EnVe Ventilator, Weighing 10 Times Less Than Traditional Critical Care Ventilators 3
(Date:12/24/2014)... Dr. Ronald Receveur, a New ... dental implants in a day, has written ... overusing teeth-whitening treatments. , In his blog published ... Receveur writes that overusing teeth-whitening treatments can lead to ... enamel. , “Because teeth-whitening treatments are available ...
(Date:12/24/2014)... News) -- Longer and colder body cooling does not reduce ... from a lack of oxygen, a new study finds. ... condition -- called hypoxic ischemic encephalopathy -- can be reduced ... Fahrenheit) for 72 hours, experts say. Research has shown ... so this study examined if the same would be true ...
(Date:12/22/2014)... December 22, 2014 B. E. Smith, ... healthcare providers, has been retained to lead a national ... Medical Center in Oceanside, Calif. The top ... E. Smith has recently placed more than 900 healthcare ... a community owned, 397-bed, Gold Seal-approved, full-service acute-care hospital ...
(Date:12/22/2014)... 22, 2014 Sagacious Consultants, the premier ... subscription option to their ad hoc report writing service ... Customers can sign up for an annual subscription and ... month at a deeply discounted hourly rate. , ... has a progressively discounted rate. Subscription hours are contracted ...
(Date:12/22/2014)... News) -- U.S. and state health officials are investigating ... killed at least four people and sickened 28 others ... commercially produced, prepackaged caramel apples until more information becomes ... said in a news release. As of Dec. ... with the outbreak strains of the bacteria Listeria ...
Breaking Medicine News(10 mins):Health News:New Albany Dentist Weighs In On New Trend of Overbleaching Teeth 2Health News:New Albany Dentist Weighs In On New Trend of Overbleaching Teeth 3Health News:Greater Cooling of Oxygen-Deprived Infants Fails to Improve Survival 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 3Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:CDC Warns of Listeria Danger From Caramel Apples 2
... Education Secretary,Gerald L. Zahorchak today issued the ... approving House Bill 1841, legislation to create,a statewide ... House Education Committee took a major step today ... care for educators,and cut down on teacher strikes," ...
... million Americans have survived a heart attack or have ... one cause of death in the United States. In ... diet and exercise, are known to reduce the risk ... proportion of heart attack survivors do not follow their ...
... Helps Drive Growth in ... Interactive Patient Care, ... of Interactive Patient Care (IPC) solutions, today announced that,Irwin Studen ... chief financial officer. With extensive experience in the,healthcare and technology ...
... back vivid, 30-year-old memories for patient, researchers say , , ... (DBS) may help improve memory, suggests a Canadian study ... prompted detailed memories in a patient. , DBS ... -- is used to treat Parkinson,s disease and other ...
... doctors as a hormone that boosts red-blood-cell production. Now, ... ophthalmologist at Children,s Hospital Boston, shows it also keeps blood ... not only add a new function to the hormone, but ... to patients with diseases affected by abnormal blood-vessel growth, such ...
... Pharmaceutical,Laboratories, Ltd. (Amex: CPD ) announced today ... mg (Pantoprazole Sodium,DR), which is AB-rated to Wyeth,s ... Ltd. (Sun Pharma). Sun Pharma recently received,approval from ... its Abbreviated,New Drug Application (ANDA) for generic Protonix(R), ...
Cached Medicine News:Health News:UMass Medical School study finds patients diagnosed with coronary heart disease continue poor diets 2Health News:UMass Medical School study finds patients diagnosed with coronary heart disease continue poor diets 3Health News:Irwin Studen Joins GetWellNetwork as Senior Vice President and Chief Financial Officer 2Health News:Irwin Studen Joins GetWellNetwork as Senior Vice President and Chief Financial Officer 3Health News:Deep Brain Stimulation May Improve Recall 2Health News:Anemia treatment may be a double-edged sword 2Health News:Anemia treatment may be a double-edged sword 3Health News:Caraco Pharmaceutical Laboratories Ltd. to Market Generic Protonix(R) 2Health News:Caraco Pharmaceutical Laboratories Ltd. to Market Generic Protonix(R) 3
For the quantitative determination of total cholesterol in serum....
Intended for the quantitative determination of total cholesterol in serum. Single vial, dry powder reagent. Reaction: Endpoint. Wavelength: 500 nm. Linearity: 700 mg/dL (12.9 mmol/L)....
This 16-bit integrated and cooled system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lighting....
... new dedicated high performance bio imaging system ... process of imaging chemiluminescent samples. It provides ... to use, thanks to new, unique image ... on the standard Genegnome, the Genegnome HR ...
Medicine Products: